CT-G32 / Celltrion - LARVOL DELTA

The next wave is scheduled to move toward regulators next year. (Korea Biomedical Review) - "Celltrion said it plans to file investigational new drug applications in early 2027 for an additional antibody-drug conjugate, CT-P74, and an FcRn inhibitor, CT-P77, and that it aims to submit a total of 12 investigational new drug applications for new-drug programs by 2028...Celltrion said it is aiming to file an investigational new drug application for CT-G32 in the second half of 2027..."

IND • Immunology • Obesity • Oncology

Celltrion steps into weight-loss market with oral rival to Wegovy, Mounjaro (KED Global) - "The company announced on Wednesday that it is developing CT-G32, an orally administered quadruple-receptor agonist designed to activate four metabolic pathways simultaneously, an approach that would move beyond the GLP-1 and dual-agonist injections, like Wegovy and Mounjaro, that dominate the global obesity drug market....Patent registrations have been completed, and formal preclinical development is planned for 2026."

New molecule • Patent • Preclinical • Obesity